April 30, 2015 - 4:02 p.m.
Gilead Sciences Declares First Quarterly Cash Dividend
Printer Friendly Version 
April 30, 2015 - 4:01 p.m.
Gilead Sciences Announces First Quarter 2015 Financial Results
Printer Friendly Version 
April 25, 2015 - 1:01 a.m.
Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5
Printer Friendly Version 
April 23, 2015 - 5:02 p.m.
Gilead Sciences to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015
Printer Friendly Version 
April 23, 2015 - 1:01 a.m.
Gilead’s Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease
Printer Friendly Version 
April 23, 2015 - 1:01 a.m.
Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C
Printer Friendly Version 
April 07, 2015 - 5:57 p.m.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment
Printer Friendly Version 
March 26, 2015 - 2:00 a.m.
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the Treatment of Genotype 2 Chronic Hepatitis C
Printer Friendly Version 
March 10, 2015 - 5:00 p.m.
Gilead Sciences to Present at the Barclays Global Healthcare Conference on Wednesday, March 11
Printer Friendly Version 
March 02, 2015 - 5:00 p.m.
Gilead Sciences to Present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3
Printer Friendly Version 
February 26, 2015 - 7:06 p.m.
Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF)
Printer Friendly Version 
February 26, 2015 - 3:16 p.m.
Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni® for the Treatment of Chronic Hepatitis C in Patients Co-Infected With HIV
Printer Friendly Version 
February 25, 2015 - 3:27 p.m.
Gilead Announces Preclinical Data for an Investigational TLR7 Agonist in SIV-Infected, Virally Suppressed Monkeys
Printer Friendly Version 
February 24, 2015 - 5:02 p.m.
Gilead Sciences to Present at the RBC Capital Markets 2015 Healthcare Conference on Wednesday, February 25
Printer Friendly Version 
February 09, 2015 - 5:01 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
February 03, 2015 - 4:07 p.m.
Gilead Sciences Announces 43 Cents Quarterly Dividend Program and $15 Billion Share Buyback Program
Printer Friendly Version 
February 03, 2015 - 4:07 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2014 Financial Results
Printer Friendly Version 
January 28, 2015 - 4:31 p.m.
Gilead Announces Executive Promotions
Printer Friendly Version 
January 27, 2015 - 5:01 p.m.
Gilead Sciences to Release Fourth Quarter and Full Year 2014 Financial Results on Tuesday, February 3, 2015
Printer Friendly Version 
January 26, 2015 - 1:01 a.m.
Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent
Printer Friendly Version 
January 12, 2015 - 5:01 p.m.
Gilead Sciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13
Printer Friendly Version 
January 06, 2015 - 8:31 a.m.
Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals’ Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Printer Friendly Version 
NASDAQ (US Dollar)
$105.66
 Stock is Up 0.65 (0.62%)
Data as of 05/04/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote